Latest news & insights
Medical monitor support and advice for FLU-v phase IIb study for influenza
Each year, influenza affects up to 5 million people worldwide and leads to an estimated 650,000 deaths. Currently, the most effective available treatment is an
Dr Bryan Murray joins Clinical and Medical Affairs Team
Dr Bryan Murray has joined Boyds as a Pharmaceutical Physician within the growing Clinical and Medical Affairs team. Bryan Murray is an experienced trials physician
Regulatory affairs team bolstered with appointment of Submissions Compliance and Quality Manager
Navila Rehman has joined Boyds as Submissions Compliance and Quality Manager within the regulatory affairs team. Navila brings over 20 years’ experience in the pharmaceutical
Virtual drug development
Nick Meyers, VP of Product Development at Boyds, spoke at a recent MarketsAndMarkets event on pragmatic drug development solutions for virtual and semi-virtual sponsors. In
IBD & Tea: building trust in new treatments
Professor Alan Boyd took part in ‘ IBD & Tea’, a recent online debate focused on building trust in new treatments and understanding clinical trials,
Nanomedicine comes of age
European researchers take nanotech-based therapies (nanomedicine) from the lab to the clinic With more than 50 nanomedicine formulations already in the market and over 400
Victoria Marsh joins the team as Director of Regulatory Affairs
Responding to sustained growth in demand for our Regulatory Services, Boyds has appointed Dr Victoria Marsh, a specialist in molecular biology and protein biochemistry, as
Boyds assists researchers and developers on COVID-19 projects
Boyds has a wealth of experience in early development and translational medicine and we are already supporting a number of vital COVID-19 projects. As this
